Overview
- Lilly’s rally, up roughly 36% this year, has been fueled by booming demand for Zepbound and Mounjaro in the fast-growing GLP-1 market.
- Third-quarter revenue rose 54% to $17.6 billion, with more than $10 billion from obesity and diabetes treatments, and the company raised full-year guidance.
- Through the first nine months of 2025, tirzepatide products generated nearly $19 billion, overtaking Keytruda to become the world’s best-selling medicine.
- Analysts highlight a recent White House pricing arrangement that could expand Medicare and Medicaid access in 2026, supporting higher volumes despite pricing pressure.
- Investors are watching the oral obesity candidate orforglipron, with some expecting approval as early as 2026, as Lilly accelerates manufacturing expansion to meet demand.